Bright Minds Biosciences (DRUG) Accounts Payables (2020 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Accounts Payables data on file, last reported at $2.7 million in Q1 2026.

• Quarterly Accounts Payables rose 600.5% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 600.5% YoY) and the FY2025 annual result came in at $1.6 million, up 447.45% from the prior year.
• Accounts Payables advanced to $2.7 million in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $2.7 million in Q1 2026 to a low of $120354.5 in Q2 2024.
• A 5-year average of $701854.8 and a median of $478983.7 in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables jumped 133240.8% — and 2023, when it slumped 85.64%.
• Tracing DRUG's Accounts Payables over 5 years: stood at $337544.0 in 2022, then surged by 74.0% to $587332.4 in 2023, then slumped by 52.61% to $278362.9 in 2024, then soared by 284.97% to $1.1 million in 2025, then surged by 155.22% to $2.7 million in 2026.
• The last three Accounts Payables figures came in at $2.7 million (Q1 2026), $1.1 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.